



ANUH PHARMA LTD.

Registered Office : 3-A, Shivsagar Estate, North Wing,
Dr. Annie Besant Road, Worli, **MUMBAI - 400 018, INDIA.**
Tel. : +91-22-6622 7575 • Fax : +91-22-6622 7600 / 7500
E-Mail : anuh@sk1932.com • CIN: L24230MH1960PLC011586

Date: 19th May, 2023

To,
The Manager (Listing)
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort, Mumbai - 400 001

Ref: Scrip Code No. 506260

Sub: Outcome of Board Meeting dated 19th May, 2023.

Dear Sir/Madam,

Pursuant to the provisions of Regulation 33 and Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, this is to inform you that the Board of Directors of the Company (the "Board") at its Meeting held today i.e. **Friday, 19th May, 2023**, inter-alia considered and approved the following agenda Items:

1. The **Audited Financial Results** for the quarter & Financial Year ended 31st March, 2023;
2. Auditor's Report on quarterly financial results and year to date results for the year ended 31st March, 2023;
3. Declaration from Joint Managing Directors w.r.t. Audit Report with unmodified opinion to the Audited Financial Results for the financial year ended 31st March, 2023;
4. Recommended final dividend of Rs. 2/- per equity share of face value of Rs. 5/- each (i.e. 40%) for the Financial Year ended 31 March, 2023, subject to the approval of the Shareholders at the ensuing Annual General Meeting of the Company;





ANUH PHARMA LTD.

Registered Office : 3-A, Shivsagar Estate, North Wing,
Dr. Annie Besant Road, Worli, **MUMBAI - 400 018, INDIA.**
Tel. : +91-22-6622 7575 • Fax : +91-22-6622 7600 / 7500
E-Mail : anuh@sk1932.com • CIN: L24230MH1960PLC011586

5. Approved the draft Notice of 63rd Annual General Meeting of the Company;
6. Appointment of M/s Sanjay Doshi & Asso., Company Secretary as Secretarial Auditors of the Company for the Financial Year 2023-24;
7. Appointment of Ankit Kishor Chande, Cost Accountant as Cost Auditor for the financial year 2023-24;
8. Re-appointment of Dr. Mita Dixit (DIN 08198165) Non Executive, Independent Director for a Second term of 5 (Five) consecutive years effective from 1st April, 2024 to 31st March, 2029;
9. Re-appointment of Mr. H. T. Patel (DIN 07342390) Non Executive, Independent Director for a Second term of 5 (Five) consecutive years effective from 22nd May, 2024 to 21st May, 2029;
10. Approved the draft Directors' Report for the financial year 2022-23;
11. Appointment of Mr. Arun L. Todarwal (DIN: 00020916) as a Non-Executive, Non-Independent, Chairman of the Company with effect from 1st April, 2024 upon his ceasing to be the Non-Executive, Independent Director of the Company w.e.f. 31st March, 2024;
12. Appointment of Mr. Pradeep Thakur (DIN: 00685992) as a Non Executive, Independent Director of the Company for a First term of 5 (Five) consecutive years effective from 1st April, 2024 to 31st March, 2029;
13. Appointment of Mr. Siddharth Shah (DIN: 00004958) as a Non Executive, Independent Director of the Company for a First term of 5 (Five) consecutive years effective from 1st April, 2024 to 31st March, 2029;
14. Appointment of Mr. Gaurav Shah (DIN: 02878186) as a Non Executive, Director of the Company with effect from 1st July, 2023.





ANUH PHARMA LTD.

Registered Office : 3-A, Shivsagar Estate, North Wing,
Dr. Annie Besant Road, Worli, **MUMBAI - 400 018, INDIA.**
Tel. : +91-22-6622 7575 • **Fax :** +91-22-6622 7600 / 7500
E-Mail : anuh@sk1932.com • **CIN:** L24230MH1960PLC011586

The Meeting of the Board of Directors commenced at 1:00 p.m. and concluded at 4:15 p.m.

Further we would like to inform that book closure intimation will be done in due course.

Thanking you,

Yours faithfully,

For **Anuh Pharma Ltd.**

Hemant Auti
Company Secretary & Compliance Officer
Encl:



Factory : E-17/3, E-17/4 & E-18, M.I.D.C., Tarapur, BOISAR, Dist. Palghar - 401 506, INDIA. **Tel.:** +91-7410055574 / 75

Independent Auditor's Report on the Quarterly and Annual Audited Financial Results of Anuh Pharma Limited (the "Company") Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To
**The Board of Directors of
Anuh Pharma Limited**

Report on the audit of the Financial Results

Opinion

We have audited the accompanying statement of quarterly and annual financial results of Anuh Pharma Limited (the "Company") for the quarter ended 31st March, 2023 and for the year ended 31st March, 2023 ("Statement"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the Statement:

- i. is presented in accordance with the requirements of the Listing Regulation 33 in this regard; and
- ii. gives a true and fair view in conformity with the applicable accounting standards and other accounting principles generally accepted in India, of the profit and other comprehensive income and other financial information of the Company for the quarter ended 31st March, 2023 and for the year ended 31st March, 2023.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013, as amended ("the Act"). Our responsibilities under those Standards are further described in the "Auditor's Responsibilities for the Audit of the Financial Results" section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion.



Management's Responsibilities for the Financial Results

The Statement has been prepared on the basis of the annual financial statements. The Board of Directors of the Company are responsible for the preparation and presentation of the Statement that gives a true and fair view of the net profit and other comprehensive loss of the Company and other financial information in accordance with the applicable accounting standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Statement, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Results

Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.



- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulation 33 of the Listing Regulations.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represents the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matter

The Statement includes the results for the quarter ended 31st March, 2023 being the balancing figure between the audited figures in respect of the full financial year ended 31st March, 2023 and the published unaudited year-to-date figures up to the third quarter of the current financial year, which were subjected to a limited review by us, as required under the Listing Regulations. Our opinion on the Statement is not modified in respect of this matter.



For JAYANTILAL THAKKAR & CO.
CHARTERED ACCOUNTANTS
(FIRM REG. NO. 104133W)

D. J. Thakkar

DILIP J. THAKKAR
PARTNER
MEMBERSHIP NO. 005369
UDIN: 23005369BGWEVQ4947

PLACE: Mumbai
DATE: 19th May, 2023

ANUH PHARMA LTD.

CIN: L24230MH1960PLC011586

Regd. Office : 3-A, North Wing, Shivsagar Estate, Dr. Annie Besant Road, Worli, Mumbai - 400018


Tel: +91 22 6622 7575; Fax: +91 22 6622 7600; Email: anuh@sk1932.com; Website: www.anuhpharma.com

AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31st MARCH, 2023

(Rs. in Lakhs)

Sr. No.	Particulars	3 months ended 31/03/2023	3 months ended 31/12/2022	3 months ended 31/03/2022	12 months ended 31/03/2023	12 months ended 31/03/2022
		Audited (Refer Note No.4)	Unaudited	Audited (Refer Note No.4)	Audited	Audited
(1)	(2)	(3)	(4)	(5)	(6)	(7)
I.	Revenue from operations	15,730.98	13,872.99	12,896.98	52,748.60	48,664.62
II.	Other income	103.72	211.26	102.89	611.45	519.71
III.	Total Revenue (I + II)	15,834.70	14,084.25	12,999.87	53,360.05	49,184.33
IV.	Expenses:					
	Cost of materials consumed	12,254.36	9,134.66	9,462.92	37,701.31	35,171.18
	Purchases of Stock-in-Trade	105.57	132.06	655.38	1,098.85	3,082.53
	Changes in inventories of finished goods, work-in-progress and Stock-in-Trade	(153.63)	1,446.64	(381.74)	1,348.08	(485.63)
	Employee benefits expense	434.93	432.44	402.02	1,715.09	1,510.05
	Finance costs	2.34	2.91	(17.72)	21.84	96.09
	Depreciation and amortization expense	240.74	243.34	300.66	970.02	1,195.97
	Other expenses	1,666.39	1,484.30	1,371.35	5,757.82	4,701.94
	Total expenses (IV)	14,550.70	12,876.35	11,792.87	48,613.01	45,272.13
V.	Profit / (Loss) before exceptional and items and tax (III - IV)	1,284.00	1,207.90	1,207.00	4,747.04	3,912.20
VI.	Exceptional items	-	-	-	-	-
VII.	Profit / (Loss) before tax (V - VI)	1,284.00	1,207.90	1,207.00	4,747.04	3,912.20
VIII.	Tax expenses:					
	(1) Current tax	381.00	276.00	360.00	1,212.00	1,058.00
	(2) Deferred tax	(59.30)	1.29	(45.55)	(82.92)	(99.46)
	(3) Income tax of earlier years	-	-	-	-	(102.47)
	Total Tax expenses (VIII)	321.70	277.29	314.45	1,129.08	856.07
IX.	Profit/(Loss) after Tax (VII-VIII)	962.30	930.61	892.55	3,617.96	3,056.13
X.	Other Comprehensive Income (net of Tax)					
	(i) Items that will not be reclassified to profit or loss	11.16	0.02	0.06	3.86	8.48
	(ii) Items that will be reclassified to profit or loss	-	-	-	-	-
	Total Other Comprehensive Income (net of Tax) (X)	11.16	0.02	0.06	3.86	8.48
XI.	Total Comprehensive Income for the period (IX + X) (Comprising Profit / (Loss) and Other Comprehensive Income for the period)	973.46	930.63	892.61	3,621.82	3,064.61
	Paid up Equity Share Capital (Face value ₹ 5/- each)	2,505.60	2,505.60	2,505.60	2,505.60	2,505.60
	Other Equity (excluding revaluation reserves)				21,616.54	18,871.68
XII.	Earnings per equity share (For respective periods) (In Rs.)					
	(1) Basic	1.92	1.86	1.78	7.22	6.10
	(2) Diluted	1.92	1.86	1.78	7.22	6.10

See accompanying notes to the financial results



Notes:-

1. The results of the quarter and year ended March 31, 2023 were reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 19th May, 2023.

2. Other Financial indicators

(Rs. in Lakhs)

Particulars	3 months ended 31/03/2023	3 months ended 31/12/2022	3 months ended 31/03/2022	12 months ended 31/03/2023	12 months ended 31/03/2022
EBITDA	1,527.08	1,454.15	1,489.94	5,738.91	5,204.26
% of EBITDA Margin	9.71	10.48	11.55	10.88	10.69
EBITDA (Adjusted to Forex (gain) / loss and Mark to Market (gain) / loss on Investment in Mutual funds)	1,494.90	1,406.69	1,519.81	5,630.55	5,241.59
% of Adjusted EBITDA Margin	9.50	10.14	11.78	10.67	10.77

3. The Board of Directors of the Company has recommended a final dividend of Rs. 2/- per equity share of face value of Rs.5 /- each (40%), subject to shareholders' approval in the forthcoming Annual General Meeting.

4. The figures for the quarter ended 31st March, 2023 and 31st March, 2022 are balancing figures between the audited figures in respect of the full financial year and the published year to date figures upto the third quarter of the relevant financial year.

5. The Company has identified Bulk drug and Chemicals as its only primary reportable segment in accordance with the requirements of Ind AS 108, 'Operating Segments'. Accordingly, no-separate segment information has been provided.

6. Previous period's figures have been regrouped and reclassified, wherever necessary, to correspond with those of the current period.

For Anuh Pharma Ltd.



Ritesh Shah
Joint Managing Director
(DIN: 02496729)



Place : Mumbai

Date : 19th May, 2023

STATEMENT OF ASSETS AND LIABILITIES

(Rs. in Lakhs)

PARTICULARS		As at 31st March, 2023	As at 31st March, 2022
		Audited	Audited
I	ASSETS		
1	Non-current Assets		
	(a) Property, Plant and equipment	5,187.20	6,018.33
	(b) Capital work-in-progress	-	10.00
	(c) Intangible Assets	13.11	18.25
	(d) Right of use assets	80.38	105.76
		5,280.69	6,152.34
	(e) Financial Assets		
	(i) Investments	3,968.40	2,121.25
	(ii) Other Financial Assets	106.90	463.51
	(f) Deferred Tax Assets (Net)	76.82	-
	(g) Income Tax Assets	246.32	111.63
	(h) Other Non Current Assets	57.70	-
	Total Non-Current Assets	9,736.83	8,848.73
2	Current Assets		
	(a) Inventories	7,263.63	7,992.33
	(b) Financial Assets		
	(i) Investments	5,115.01	2,146.89
	(ii) Trade receivables	17,122.75	13,570.83
	(iii) Cash and cash equivalents	192.68	379.58
	(iv) Other Bank balances	472.48	1,215.24
	(v) Loans and Advances	47.41	78.82
	(vi) Other financial assets	10.27	52.51
	(c) Other current assets	536.96	432.50
	Total Current Assets	30,761.19	25,868.70
	TOTAL ASSETS	40,498.02	34,717.43
II	EQUITY AND LIABILITIES		
	EQUITY		
	(i) Equity Share Capital	2,505.60	2,505.60
	(ii) Other Equity	21,616.54	18,871.68
	TOTAL EQUITY	24,122.14	21,377.28
	Liabilities		
1	NON-CURRENT LIABILITIES		
	(a) Financial Liabilities		
	(i) Lease Liabilities	83.94	90.67
	(b) Provisions	158.41	154.09
	(c) Deferred Tax Liabilities(Net)	-	4.81
	TOTAL NON-CURRENT LIABILITIES	242.35	249.57
2	CURRENT LIABILITIES		
	(a) Financial Liabilities		
	(i) Borrowings	-	311.10
	(ii) Lease Liabilities	6.73	20.58
	(iii) Trade Payables:		
	Due to Micro and Small Enterprises	5.48	14.92
	Due to other than Micro and Small Enterprises	15,271.03	12,142.50
	(iv) Other financial liabilities	482.61	420.16
	(b) Other current liabilities	361.06	175.58
	(c) Provisions	6.62	5.74
	TOTAL CURRENT LIABILITIES	16,133.53	13,090.58
	TOTAL EQUITY AND LIABILITIES	40,498.02	34,717.43



ANUH PHARMA LIMITED
CASH FLOW STATEMENT FOR THE YEAR ENDED 31st MARCH, 2023

(Rs. in Lakhs)

Particulars	Year ended 31st March, 2023		Year ended 31st March, 2022	
	Audited		Audited	
(A) CASH FLOW FROM OPERATING ACTIVITIES:				
NET PROFIT BEFORE TAX		4,747.04		3,912.20
Adjustment for:				
Depreciation and Amortization	970.02		1,195.97	
Finance Costs	21.84		96.09	
Interest Income	(44.98)		(104.48)	
Market to Market (gain) / loss on investment (Net)	(323.00)		(127.57)	
Market to Market loss / (gain) on Derivative (Net)	15.55		-	
Provision for Gratuity & Leave Encashment	36.40		39.54	
Doubtful Debts Provision written back	(19.98)		(5.11)	
Dividend Income	(104.84)		(135.31)	
(Profit)/Loss on Sale of Property, Plant and Equipment (Net)	(1.49)		(6.16)	
(Profit)/Loss on Sale of Investment (Net)	(110.86)		(136.10)	
		438.66		816.86
OPERATING PROFIT BEFORE WORKING CAPITAL CHANGES		5,185.70		4,729.06
Adjustment for:				
Trade and Other Receivables	(3,531.95)		(2,879.64)	
Inventories	728.70		150.25	
Other Financial Assets	1,109.15		720.89	
Loans and Advances	31.41		14.16	
Other Current Assets	(104.46)		833.02	
Trade Payables	3,119.09		155.84	
Other Financial Liabilities	39.76		30.32	
Other current Liabilities	185.49		75.75	
Gratuity & Leave Encashment paid	(26.04)		(29.46)	
		1,551.15		(928.87)
CASH GENERATED FROM OPERATIONS		6,736.85		3,800.19
Direct Taxes paid (Net)	(1,346.69)	(1,346.69)	(913.82)	(913.82)
NET CASH FROM OPERATIONS		5,390.16		2,886.37
(B) CASH FLOW FROM INVESTING ACTIVITIES:				
(Purchase)/Sale of Investments [net]	(4,381.40)		(865.89)	
Purchase of Property, Plant and Equipment and Capital Work in Progress	(155.01)		(161.48)	
Sale of Property, Plant and Equipment	5.66		14.30	
Interest Income	77.54		96.04	
Dividend Income	104.84		135.31	
NET CASH (USED IN) INVESTING ACTIVITIES		(4,348.37)		(781.71)
(C) CASH FLOW FROM FINANCING ACTIVITIES:				
Total repayments to Borrowings (net of proceeds):				
Secured Loans/Short Term Borrowings	(311.10)		(1,048.67)	
Payment of Lease Liabilities	(30.79)		(33.53)	
Finance Costs	(11.97)		(106.94)	
Dividend paid	(874.83)		(755.77)	
NET CASH (USED IN) / GENERATED FROM FINANCING ACTIVITIES		(1,228.69)		(1,944.92)
NET (DECREASE) / INCREASE IN CASH AND CASH EQUIVALENTS (A + B + C)		(186.90)		159.74
CASH AND CASH EQUIVALENT AS AT THE BEGINNING OF THE PERIOD		379.58		219.84
CASH AND CASH EQUIVALENT AS AT THE END OF THE PERIOD		192.68		379.58